• GSK 2837808A: LDHA Inhibition Workflow

  2026-08-22

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor for dissecting lactate production, glucose consumption, and tumor–immune signaling. This workflow translates its biochemical selectivity into practical cell-based assays for cancer metabolism research while addressing exposure, solubility, and pathway-specific interpretation.

• MRT68921: Turning Autophagy Off to See It Clearly

  2026-08-21

  Autophagy research is moving from descriptive imaging toward causal pathway analysis. This thought-leadership article explains how MRT68921, a dual ULK1/2 inhibitor, can help translational researchers connect ULK signaling with lipid metabolism, ATG13 phosphorylation, and LC3 flux while maintaining appropriate preclinical boundaries.

• Astrocytic GAT-3 Controls Dentate Gyrus Memory

  2026-08-20

  The reference study identifies astrocytic GAT-3 as an active regulator of dentate gyrus synaptic transmission rather than simply a GABA clearance system. Combining electrophysiology, optogenetics, calcium signaling analysis, immunohistochemistry, and contextual fear assays, the authors connect GAT-3-dependent astrocytic Ca2+ signaling with GluN2B-NMDAR-mediated excitation and memory formation.

• Gut-Brain Cholinergic Signaling in Epilepsy

  2026-08-20

  Jia et al. identify a microbiota–vagus–brain cholinergic circuit through which oral Bacteroides fragilis suppresses seizures in mouse models and improves outcomes in a pediatric refractory epilepsy trial. The study links colonic ChAT-positive cells, vagal transmission, and Lactobacillus enrichment, providing a mechanistic framework for microbiota-targeted epilepsy research.

• Nonivamide: TRPV1 Assay Design Beyond Cancer

  2026-08-19

  Nonivamide is a capsaicin analog that connects TRPV1 pharmacology with cancer cell growth inhibition and neuroimmune assay design. This article explains how to distinguish direct apoptosis from circuit-level inflammation effects and how to build more interpretable workflows.

• Puromycin Dihydrochloride: Assay Logic

  2026-08-19

  Puromycin dihydrochloride is more than a selection reagent: it is a mechanistic probe for translation, ribosome behavior, and experimental confounding. This article shows how to separate antibiotic selection from phenotype measurement, using telomere biology research as a model for better assay design.

• Prochlorperazine: From Antiemesis to Assay Logic

  2026-08-18

  Prochlorperazine is a dopamine D2 receptor antagonist with applications spanning antiemetic therapy and experimental melanoma research. This article develops a temporal, mechanism-aware framework for translating its pharmacology into more interpretable cell-based assays.

• ARCA Cy3 EGFP mRNA (5-moUTP): Cell Assays

  2026-08-18

  This scenario-driven guide shows how ARCA Cy3 EGFP mRNA (5-moUTP), SKU R1008, can separate mRNA uptake, intracellular trafficking, translation, and assay-related cytotoxicity in mammalian cell workflows. It combines practical handling parameters with evidence-based interpretation and vendor-selection criteria.

• Palmitic acid: Practical Protocol and QC Guide

  2026-08-17

  Palmitic acid (SKU N2456), also known as hexadecanoic acid, provides a characterized saturated long-chain fatty acid for controlled studies of lipid metabolism, protein palmitoylation, metabolic disorder research, and inflammation signaling studies. It is intended for solvent-based preparation rather than direct aqueous dissolution or long-term solution storage, so matched vehicle controls and prompt use are essential.

• Oxaliplatin Workflows for Resistance Research

  2026-08-17

  Build more reproducible Oxaliplatin assays by combining controlled DNA-damage exposure, resistance modeling, organoid validation, and mechanism-aware combination testing. This workflow translates evidence on CDK1, PARP1, and olaparib sensitivity into practical choices for cancer chemotherapy research.

• Cell lysis buffer for WB and IP in CAF Studies

  2026-08-16

  Cell lysis buffer for WB and IP can support mechanistic studies of cancer-associated fibroblast signaling by combining non-denaturing extraction with protease and phosphatase inhibition. This guide translates the ANGPTL4-IQGAP1 prostate cancer findings into practical decisions for Western blotting, immunoprecipitation, co-IP, and ELISA.

• Epalrestat and Fructose Metabolism: Assay Strategy

  2026-08-15

  Epalrestat is an aldose reductase inhibitor that enables researchers to interrogate the upstream polyol pathway, oxidative stress, and endogenous fructose generation. This article translates recent cancer-metabolism findings into a rigorous assay strategy while defining the limits of extrapolating diabetic neuropathy and neuroprotection data to oncology.

• Rapid Recombinant Annexin V Purification: Study Analysis

  2026-08-14

  Burger and colleagues developed a short purification workflow for recombinant annexin V that combines mild osmotic shock, reversible calcium-dependent liposome binding, and final ion-exchange chromatography. The approach produced protein sufficiently pure for electrophysiology, crystallography, electron microscopy, and related biophysical studies, illustrating how functional properties can be used as purification handles.

• Carfilzomib (PR-171): Translational Strategy

  2026-08-14

  A mechanistic and strategic guide to using Carfilzomib (PR-171) to study proteasome dependence, proteotoxic stress, apoptosis, and combination opportunities in translational cancer research.

• MK-5108 (VX-689) for Aurora A Research

  2026-08-13

  MK-5108 (VX-689) combines a subnanomolar Aurora A potency profile with practical workflows for cell-cycle, proliferation, retinoblastoma, and xenograft studies. This guide translates Aurora A biology into assay design, dosing, controls, and troubleshooting decisions for reproducible cancer research.

7969 records 9/532 page Previous Next First page 上5页 678910 下5页 Last page